These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26769867)

  • 1. Evaluation of the Efficacy of Targeted Imaging Agents.
    Graham MM; Weber WA
    J Nucl Med; 2016 Apr; 57(4):653-9. PubMed ID: 26769867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA cGMP requirements for PET drugs.
    Norenberg JP; Schwarz S; VanBrocklin H
    J Nucl Med; 2011 May; 52(5):16N. PubMed ID: 21536923
    [No Abstract]   [Full Text] [Related]  

  • 4. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
    Barrio JR; Marcus CS; Hung JC; Keppler JS
    Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticals.
    Gorovets A; Marzella L; Rieves D; Yang L
    J Nucl Med; 2013 Aug; 54(8):1479-84. PubMed ID: 23749997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The food and drug administration and molecular imaging agents: potential challenges and opportunities.
    Henderson JA; Alexander BC; Smith JJ
    J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.
    Zhu S; Mosessian S; Kroeger K; Sadeghi S; Slavik R; Kinloch S; Moore M; Allen-Auerbach M; Czernin J; Phelps M
    Mol Imaging Biol; 2020 Apr; 22(2):256-264. PubMed ID: 31240531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring; extension of comment period--FDA. Proposed rule; extension of comment period.
    Fed Regist; 1998 Aug; 63(148):41219-20. PubMed ID: 10181522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do we introduce the next generation of radiotracers into clinical practice?
    McEwan AJ
    J Nucl Med; 2007 Sep; 48(9):28N, 30N. PubMed ID: 17785722
    [No Abstract]   [Full Text] [Related]  

  • 16. An imaging agent for amyloid.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):54-5. PubMed ID: 22777304
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory Agencies and PET/CT Imaging in the Clinic.
    Herscovitch P
    Curr Cardiol Rep; 2022 Oct; 24(10):1361-1371. PubMed ID: 35913674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final PET CGMP regulation.
    Breslow K; Schwarz SW
    J Nucl Med; 2010 Mar; 51(3):15N-6N. PubMed ID: 20197439
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"?
    Nutt R; Vento LJ; Ridinger MH
    Clin Pharmacol Ther; 2007 Jun; 81(6):792-5. PubMed ID: 17505491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.